I would tend to agree. But the CFO was downplaying Research significantly:

“How dependent is that acceleration on a recovery in the academic markets in your mind…”

“As we looked and set the model expectations… we always assumed that research would be a low growth market for us… the growth is really weighted toward the applied markets and in particular growing quicker in clinical, applied and BioPharma”…”even from where we are today we’re seeing real good adoption in places like rare disease an oncology”…”when we look at the 13 to 14 billion dollars of high priority segments”…” a big chunk of it is in that clinical space.”